NCT07105735 - RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

December 31, 2027

Conditions

Autoimmune Diseases Refractory to Standard Therapies

Interventions

BIOLOGICAL

allogeneic CAR-T

Fludarabine injection (30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before RN1201 infusion.

Trial Locations (1)

The First Affiliated Hospital with Nanjing Medical University, Nanjing